Publication | Open Access
Safety and Efficacy of Tralokinumab in Older Adults With Moderate-to-Severe Atopic Dermatitis
20
Citations
8
References
2023
Year
The results of this post hoc analysis suggest that tralokinumab is well tolerated and efficacious in patients 65 years or older with moderate-to-severe AD.
| Year | Citations | |
|---|---|---|
Page 1
Page 1